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Authors’ letter provides further evidence that 
language for trial phase would appear necessary 
when searching for RCT 
 
Thompson and Scott (2019) suggest including “additional search filters which are more 
frequently utilised in systematic reviews” in our case study; we question if it is possible to 
determine which of the many search filters available for randomised controlled trials (RCT) 
are the most frequently used in systematic reviews. It is not mandatory to reference search 
filters, so we cannot use citation count as an imperfect proxy, and we are not aware of any 
evidence which ranks search filters according to use. In fact, study authors seldom provide 
a justification for the selection of a search filter (1, 2) and adapting search filters is common 
practice (3), such that it is often unclear if the search filter used in a systematic review bears 
fidelity to any established search filter, or if it is an assembly of many different search 
filters, (4, 5). Guidance on how to cite search filters, and when to cite search filters which 
combine components of various search filters, would be welcome.  
 
We contend that the Cochrane HSSS are the original RCT search filters. Developed and 
published in 1994, the filters not only set out a strategy of search terms to identify 
controlled trials for the first time but also the team behind the HSSS was instrumental in 
adapting the architecture, and developing the process, which underpins the identification 
of controlled studies in bibliographic databases (c.f. (6-16)). The BRSS and SIGN filters 
acknowledge this heritage (17-21), and we suggest that this is justification for the use of the 
term ‘established’ in our case study.    
 
Thompson and Scott (2019) suggest that the SIGN and the CADTH RCT filters “include the 
very terms” that we suggest for the P3 filter and that the SIGN and CADTH filters would 
capture the types of study we identified in our original publication and which the HSSS and 
BRSS missed. The authors also question why we did not compare the P3 filter to search 
filters which already use language for trial phase.  
 
To respond to these criticisms, we present further analyses here where we compare the P3 
filter to:  
 
 the SIGN RCT filter (21);  
 the CADTH RCT filter, pre-April 2018; and 
 the CADTH CCT/RCT Filter April 2018 (22).  
 
We include the pre-April 2018 CADTH filter as Thompson and Scott suggest that, even prior 
to the 2018 update, the CADTH RCT filter would capture the studies missed by the HSSS 
and BRSS, as reported in our article (23). This pre-2018 version of the filter was provided by 
CADTH.  
 
Before we present the comparisons, it is important to note one point. As is set out in our 
article, the P3 filter was initially presented at the 2016 Health Technology Assessment 
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international (HTAi) conference in Tokyo, Japan. Members of CADTH staff attended this 
presentation and we are advised that our presentation directly influenced CADTH’s 
decision to include terms for trial phase when their CCT/RCT search filter was updated in 
April 2018 (see lines 1 and 31 of the CADTH CCT/RCT Filter April 2018). 
 
Extending the analysis of the P3 filter  
 
Methods 
The search strategies for the new analyses were:  
 
1. search filter 
2. unique identifier codes for the seven studies missed by the HSSS and BRSS in our article 
3. 1 and 2 
4. 2 NOT 3 
 
Line 4 would identify any studies picked up by the P3 filter but missed by the SIGN or 
CADTH filters. The search strategies are reported in supplementary material and using a 
search narrative for clarity of reporting (24).  
 
Results 
The three search filters were run in MEDLINE (Ovid interface) on August 12th 2019. The 
results are presented in Table One.  
 
Table 1 results from comparing the P3 filter to the SIGN and CADTH filters 
Seven marker 








Attard et al 2015 
(25) 
✓ ✓ ✓ ✓ 
He et al. 2015 (26) ✓ ✓ ✓ ✓ 
Kim et al. 2015 
(27) 
X X ✓ ✓ 
Kuhle et al 2015 
(28) 
✓ ✓ ✓ ✓ 
Nasr et al. 2015 
(29) 
X X ✓ ✓ 
Tarhini et al. 2015 
(30) 
✓ X ✓ ✓ 
Zhang et al. 2015 
(31) 
✓ ✓ ✓ ✓ 
Key: ✓ identified; X still missed 
 
Both the SIGN and CADTH pre-April 2018 filters missed studies, in particular the RCT by 
Nasr et al. This challenges the suggestion of Thompson and Scott and it adds further 
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support for our findings, namely, that including language for trial phase would appear to 
improve sensitivity when searching for RCT. 
 
The CADTH April 2018 filter identifies all seven studies missed by the HSSS/BRSS in our 
original article. CADTH’s April 2018 filter includes language for trial phase (see lines 1 and 
31) in a way similar to the P3 filter, since it is based on the work we presented in 2016 and 
subsequently published in 2019. In addition to phase III terminology, the CADTH CCT/RCT 
April 2018 filter also incorporates several MeSH and keywords related to controlled clinical 
trials (in lines 1, 5, 6, 7, 18, 19, 23, 24, 25, 26 and 30) as compared to the CADTH pre-2018 
RCT filter. 
 
There are differences between the P3 filter and CADTH’s consideration of our work. 
CADTH’s use of phase III terminology in the April 2018 filter did not retrieve the study by 
Zhang et al.. However, CADTH’s April 2018 filter does retrieve this article with terminology 
for open-label extension studies at line 26.  
 
Summary 
The analyses presented here provide further evidence for the importance of using language 
for trial phase when searching for RCT. This would appear to add strength to our original 
findings (23).  
 
We would agree with Thompson and Scott that it is important reviewers understand the 
limitations of search filters. As we have demonstrated here, this is not always clear from 
simply reading them. Guidance suggests that information specialists are well-placed to 




Mr Chris Cooper 1 
Mr David Kaunelis 2 
Dr Jo Varley Campbell 1 
Dr Patrice Carter 1 
 
1 Department of Clinical, Educational and Health Psychology, University College London, 
London WC1E 7HB, UK 
2 Canadian Agency for Drugs and Technologies in Health. 600-865 Carling Ave., Ottawa ON 
K1S 5S8 Canada. 
 
References   
1. Harbour J, Fraser C, Lefebvre C, Glanville J, Beale S, Boachie C, et al. Reporting 
methodological search filter performance comparisons: a literature review. Health 
Information & Libraries Journal. 2014;31(3):176-94. 
2. Cooper C, Varley-Campbell J, Booth A, Britten N, Garside R. Systematic review 
identifies six metrics and one method for assessing literature search effectiveness but no 
consensus on appropriate use. J Clin Epidemiol. 2018;99:53-63. 
3. Jenkins M. Evaluation of methodological search filters--a review. Health Info Libr J. 
2004;21(3):148-63. 
 4 
4. Lefebvre C, Glanville J, Beale S, Boachie C, Duffy S, Fraser C, et al. Assessing the 
performance of methodological search filters to improve the efficiency of evidence 
information retrieval: five literature reviews and a qualitative study. Health Technol Assess. 
2017;21(69):1-148. 
5. Jenkins M, Johnson F. Awareness, use and opinions of methodological search filters 
used for the retrieval of evidence-based medical literature—a questionnaire survey. Health 
Information & Libraries Journal. 2004;21(1):33-43. 
6. Lefebvre C. Identification of randomized controlled trials using MEDLINE: the 
situation in 1993. Bethesda MD,: National Institutes of Health, Office of Medical 
Applications of Research; 1993.   
7. Adams CE, Frederick K. An investigation of the adequacy of MEDLINE searches for 
randomized controlled trials (RCTs) of the effects of mental health care. Psychological 
Medicine. 1994;24(3):741-8. 
8. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic 
reviews. BMJ: British Medical Journal. 1994;309(6964):1286-91. 
9. Lefebvre C, Eisinga A, McDonald S, Paul N. Enhancing access to reports of 
randomized trials published world-wide – the contribution of EMBASE records to the 
Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library. 
Emerging Themes in Epidemiology. 2008;5:13. 
10. Glanville JM, Lefebvre C, Miles JNV, Camosso-Stefinovic J. How to identify 
randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library 
Association. 2006;94(2):130-6. 
11. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins 
JPT, Green S. (eds.) Cochrane Handbook for Systematic Reviews of Interventions Version 
5.1.0 (updated March 2011). The Cochrane Collaboration; 2011 [Accessed 7th December 
2017]. Available from: http://handbook.cochrane.org/  
12. Lefebvre C, Glanville J, Wieland LS, Coles B, Weightman AL. Methodological 
developments in searching for studies for systematic reviews: past, present and future? 
Systematic Reviews. 2013;2:78. 
13. Wieland S, Dickersin K. Why were they missed? Randomized controlled trials 
(RCTs) identified through the MEDLINE Retagging Project but not the US National Library 
of Medicine (NLM). Paper presented at: Proceedings of the 16th Cochrane Colloquium; 
2008 Oct 3-7; Freiburg, Germany. 
14. Dickersin K, Manheimer E, Wieland S, Robinson KA, Lefebvre C, McDonald S. 
Development of the Cochrane Collaboration's CENTRAL Register of controlled clinical 
trials. Eval Health Prof. 2002;25(1):38-64. 
15. Wieland LS, Robinson KA, Dickersin K. Understanding why evidence from 
randomised clinical trials may not be retrieved from Medline: comparison of indexed and 
non-indexed records. BMJ: British Medical Journal. 2012;344. 
16. Clunie G, Ludbrook J, Faris I. The reporting of randomized controlled clinical trials 
and The Cochrane Collaboration. Australian and New Zealand Journal of Surgery. 
1995;65(7):461-2. 
17. Royle P, Bain L, Waugh N. Systematic reviews of epidemiology in diabetes: finding 
the evidence. BMC Med Res Methodol. 2005;5:2. 
18. Royle P, Milne R. Literature searching for randomized controlled trials used in 
Cochrane reviews: rapid versus exhaustive searches. Int J Technol Assess Health Care. 
2003;19(4):591-603. 
19. Royle P, Waugh N. A simplified search strategy for identifying randomised controlled 
trials for systematic reviews of health care interventions: a comparison with more exhaustive 
strategies. BMC Med Res Methodol. 2005;5:23. 
 5 
20. Royle PL, Waugh NR. Making literature searches easier: a rapid and sensitive search 
filter for retrieving randomized controlled trials from PubMed. Diabet Med. 2007;24(3):308-
11. 
21. Healthcare Improvement Scotland: SIGN. Search Filters Edinburgh: Healthcare 
Improvement Scotland: SIGN; 2019 [Jul 19]. Available from: https://www.sign.ac.uk/search-
filters.html 
22. CADTH. Strings attached: CADTH's database search filters. 2019. [Accessed 8th 
August 2019] Available from: https://www.cadth.ca/resources/finding-evidence/strings-
attached-cadths-database-search-filters  
23. Cooper C, Varley-Campbell J, Carter P. Established search filters may miss studies 
when identifying randomised controlled trials. Journal of Clinical Epidemiology. 
2019;112(August):12-9. 
24. Cooper C, Dawson S, Peters J, Varley-Campbell J, Cockcroft E, Hendon J, et al. 
Revisiting the need for a literature search narrative: A brief methodological note. Res Synth 
Methods. 2018;9(3):361-5. 
25. Attard G, de Bono JS, Logothetis CJ, Fizazi K, Mukherjee SD, Joshua AM, et al. 
Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in 
Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate. 
Clinical Cancer Research. 2015;21(7):1621-7. 
26. J. He, L. Xiu, P. De Porre, R. Dass, X. Thomas 
Decitabine reduces transfusion dependence in older patients with acute myeloid leukemia: 
results from a post hoc analysis of a randomized phase III study 
Leuk Lymphoma, 56 (4) (2015), pp. 1033-104227. 
27.  Kim ST, Jang KT, Lee J, Jang HM, Choi HJ, Jang HL, et al. Molecular Subgroup 
Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or 
without Erlotinib in Advanced Biliary Tract Cancer. Translational Oncology. 2015;8(1):40-6. 
28. Kuhle J, Disanto G, Lorscheider J, Stites T, Chen Y, Dahlke F, et al. Fingolimod and 
CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology. 
2015;84(16):1639-43. 
29. Nasr KE, Osman MA, Elkady MS, Ellithy MA. Metronomic methotrexate and 
cyclophosphamide after carboplatin included adjuvant chemotherapy in triple negative breast 
cancer: a phase III study. Annals of Translational Medicine. 2015;3(19):284. 
30. Tarhini AA, Lin Y, Zahoor H, Shuai Y, Butterfield LH, Ringquist S, et al. Pro-
Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-alpha 
but Not Observation in Intermediate Risk Melanoma Patients. PLoS ONE [Electronic 
Resource]. 2015;10(7):e0132745. 
31. Zhang Z, Wang J, Zhang X, Chen S, Wang Z, Zhang B, et al. An open-label extension 
study to evaluate the safety of ropinirole prolonged release in Chinese patients with advanced 
Parkinson's disease. Current Medical Research & Opinion. 2015;31(4):723-30. 
32. Cooper C, Booth A, Varley-Campbell J, Britten N, Garside R. Defining the process to 
literature searching in systematic reviews: a literature review of guidance and supporting 
studies. BMC Medical Research Methodology. 2018;18(1):85. 
 
